Richard Ammer - Publications

Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet® MR and Concerta®) - a Danish nationwide register-based cohort study.

Journal: Scandinavian journal of child and adolescent psychiatry and psychology

Published: November 25, 2024

Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).

Journal: CNS drugs

Published: November 03, 2024

ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?

Journal: BMC psychiatry

Published: October 27, 2023

The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: October 20, 2022

Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.

Journal: Clinical kidney journal

Published: August 23, 2022

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: January 28, 2022

Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial.

Journal: Kidney international reports

Published: November 16, 2020

Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: November 29, 2019